跳至主要内容
临床试验/NCT02668393
NCT02668393已完成1 期

An Open Label Phase I of Oral Nintedanib Plus Weekly Docetaxel Therapy in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma After Failure of Platinum -Based First Line Chemotherapy

Boehringer Ingelheim4 个研究点 分布在 2 个国家目标入组 14 人开始时间: 2016年3月7日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
14
试验地点
4
主要终点
Maximum Tolerated Dose (MTD) of Nintedanib Administered in Combination With Docetaxel

研究概览

简要总结

Phase I study. To determine the MTD (Maximum Tolerated Dose) of nintedanib + weekly Docetaxel in patients with locally advanced or metastatic lung adenocarcinoma after failure of platinum-based first line chemotherapy.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Level 0

Other

Nintedanib low dose with docetaxel

干预措施: Docetaxel (Drug)

Level 0

Other

Nintedanib low dose with docetaxel

干预措施: Nintedanib (Drug)

Level 1

Other

Nintedanib medium dose with docetaxel

干预措施: Docetaxel (Drug)

Level 1

Other

Nintedanib medium dose with docetaxel

干预措施: Nintedanib (Drug)

Level 2

Other

Nintedanib high dose with docetaxel

干预措施: Docetaxel (Drug)

Level 2

Other

Nintedanib high dose with docetaxel

干预措施: Nintedanib (Drug)

Level 3

Other

Nintedanib continuous high dose with docetaxel

干预措施: Docetaxel (Drug)

Level 3

Other

Nintedanib continuous high dose with docetaxel

干预措施: Nintedanib (Drug)

结局指标

主要结局

Maximum Tolerated Dose (MTD) of Nintedanib Administered in Combination With Docetaxel

时间窗: First treatment cycle, the first 28 days following the start of trial medication.

Maximum tolerated dose (MTD) of nintedanib administered in combination with docetaxel. The MTD was defined as the highest dose combination studied for which the incidence of DLTs was no more than 1 out of 6 subjects experiencing a DLT during the first treatment cycle i.e. the incidence of DLTs was no more than 17%. In case dose escalation reached dose level 3 (200 mg bid nintedanib administered without interruption on days of docetaxel infusion) and no more than 1 out of 6 subjects experienced a DLT during the first 28-day cycle at this dose level, dose level 3 was considered the MTD.

Number of Participants With Dose-limiting Toxicity (DLT) During the First Treatment Cycle

时间窗: First treatment cycle, the first 28 days following the start of trial medication.

Number of participants with DLT occurring during the first treatment cycle. DLT was defined as any of the following adverse events related to nintedanib: * Non-haematological drug-related Common Terminology Criteria for AEs (CTCAE) grade 3 or greater * diarrhoea CTCAE grade 2 for \>7 days despite supportive care * nausea CTCAE grade 3 or greater despite supportive care * vomiting CTCAE grade 2 or greater despite supportive care * increase in Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) to CTCAE grade 3 or greater * A increase in ALT and/or AST to CTCAE grade 2 or greater in conjunction with * total bilirubin increase of CTCAE grade 1 or greater * Platelets \<50 000/mm3 with bleeding (CTCAE ≥3) * neutropenia of any grade or duration accompanied by fever \>38.5°C * neutropenia grade 4 without fever of \>7 days duration * Inability to resume nintedanib dosing within 21 days after stopping due to toxicity.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验